{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:56:03Z","timestamp":1794851763438,"version":"4.9.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Third Xiangya Hospital Xiangya School of Medicine","id":[{"id":"https:\/\/ror.org\/05akvb491","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000053","name":"U.S. Department of Health & Human Services | NIH | National Eye Institute","doi-asserted-by":"publisher","award":["R01EY030991"],"award-info":[{"award-number":["R01EY030991"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/05p26gw61","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000053","name":"U.S. Department of Health & Human Services | NIH | National Eye Institute","doi-asserted-by":"publisher","award":["R01EY030991"],"award-info":[{"award-number":["R01EY030991"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/05p26gw61","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["UG3MH120094"],"award-info":[{"award-number":["UG3MH120094"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/033jnv181","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P30 EY08098"],"award-info":[{"award-number":["P30 EY08098"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/033jnv181","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","award":["Career Development Award"],"award-info":[{"award-number":["Career Development Award"]}],"id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001116","name":"Foundation Fighting Blindness","doi-asserted-by":"publisher","award":["Individual Investigator Award"],"award-info":[{"award-number":["Individual Investigator Award"]}],"id":[{"id":"10.13039\/100001116","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health","id":[{"id":"https:\/\/ror.org\/033jnv181","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001607","name":"Eye and Ear Foundation of Pittsburgh","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001607","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Eye Institute","id":[{"id":"https:\/\/ror.org\/05p26gw61","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Mutations in\n                    <jats:italic>PRPF31<\/jats:italic>\n                    cause autosomal dominant retinitis pigmentosa, an untreatable form of blindness. Gene therapy is a promising treatment for PRPF31-retinitis pigmentosa, however, there are currently no suitable animal models in which to develop AAV-mediated gene augmentation. Here we establish\n                    <jats:italic>Prpf31<\/jats:italic>\n                    mutant mouse models using AAV-mediated CRISPR\/Cas9 knockout, and characterize the resulting retinal degeneration phenotype. Mouse models with early-onset morphological and functional impairments like those in patients were established, providing new platforms in which to investigate pathogenetic mechanisms and develop therapeutic methods. AAV-mediated\n                    <jats:italic>PRPF31<\/jats:italic>\n                    gene augmentation restored the retinal structure and function in a rapidly degenerating mouse model, demonstrating the first in vivo proof-of-concept for AAV-mediated gene therapy to treat PRPF31-retinitis pigmentosa. AAV-CRISPR\/Cas9-PRPF31 knockout constructs also mediated efficient\n                    <jats:italic>PRPF31<\/jats:italic>\n                    knockout in human and non-human primate retinal explants, laying a foundation for establishing non-human primate models using the method developed here.\n                  <\/jats:p>","DOI":"10.1038\/s41467-022-35361-8","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T22:02:43Z","timestamp":1670882563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Gene augmentation prevents retinal degeneration in a CRISPR\/Cas9-based mouse model of PRPF31 retinitis pigmentosa"],"prefix":"10.1038","volume":"13","author":[{"given":"Zhouhuan","family":"Xi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4797-2136","authenticated-orcid":false,"given":"Abhishek","family":"Vats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4831-1153","authenticated-orcid":false,"given":"Jos\u00e9-Alain","family":"Sahel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3229-4993","authenticated-orcid":false,"given":"Leah C.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"key":"35361_CR1","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/cge.12758","volume":"90","author":"AM Rose","year":"2016","unstructured":"Rose, A. M. & Bhattacharya, S. S. Variant haploinsufficiency and phenotypic non-penetrance in PRPF31-associated retinitis pigmentosa. Clin. Genet. 90, 118\u2013126 (2016).","journal-title":"Clin. Genet."},{"key":"35361_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/978-1-4419-1399-9_29","volume":"664","author":"I Golovleva","year":"2010","unstructured":"Golovleva, I., K\u00f6hn, L., Burstedt, M., Daiger, S. & Sandgren, O. Mutation spectra in autosomal dominant and recessive retinitis pigmentosa in northern Sweden. Adv. Exp. Med. Biol. 664, 255\u2013262 (2010).","journal-title":"Adv. Exp. Med. Biol."},{"key":"35361_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ophtha.2003.05.010","volume":"111","author":"H Buch","year":"2004","unstructured":"Buch, H. et al. Prevalence and causes of visual impairment and blindness among 9980 Scandinavian adults: the Copenhagen City Eye Study. Ophthalmology 111, 53\u201361 (2004).","journal-title":"Ophthalmology"},{"key":"35361_CR4","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/j.ophtha.2020.04.008","volume":"127","author":"N Pontikos","year":"2020","unstructured":"Pontikos, N. et al. Genetic basis of inherited retinal disease in a molecularly characterized cohort of more than 3000 families from the United Kingdom. Ophthalmology 127, 1384\u20131394 (2020).","journal-title":"Ophthalmology"},{"key":"35361_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/09286580591005813","volume":"12","author":"JI Al-Merjan","year":"2005","unstructured":"Al-Merjan, J. I., Pandova, M. G., Al-Ghanim, M., Al-Wayel, A. & Al-Mutairi, S. Registered blindness and low vision in Kuwait. Ophthalmic Epidemiol. 12, 251\u2013257 (2005).","journal-title":"Ophthalmic Epidemiol."},{"key":"35361_CR6","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/S0140-6736(06)69740-7","volume":"368","author":"DT Hartong","year":"2006","unstructured":"Hartong, D. T., Berson, E. L. & Dryja, T. P. Retinitis pigmentosa. Lancet 368, 1795\u20131809 (2006).","journal-title":"Lancet"},{"key":"35361_CR7","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1167\/iovs.18-23854","volume":"59","author":"I Martin-Merida","year":"2018","unstructured":"Martin-Merida, I. et al. Toward the mutational landscape of autosomal dominant retinitis pigmentosa: a comprehensive analysis of 258 spanish families. Invest Ophthalmol. Vis. Sci. 59, 2345\u20132354 (2018).","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"35361_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-1-40","volume":"1","author":"C Hamel","year":"2006","unstructured":"Hamel, C. Retinitis pigmentosa. Orphanet J. Rare Dis. 1, 40 (2006).","journal-title":"Orphanet J. Rare Dis."},{"key":"35361_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ajo.2018.12.009","volume":"200","author":"K Kiser","year":"2019","unstructured":"Kiser, K. et al. Time course of disease progression of PRPF31-mediated retinitis pigmentosa. Am. J. Ophthalmol. 200, 76\u201384 (2019).","journal-title":"Am. J. Ophthalmol."},{"key":"35361_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3109\/13816810.2012.762932","volume":"34","author":"VM Utz","year":"2013","unstructured":"Utz, V. M., Beight, C. D., Marino, M. J., Hagstrom, S. A. & Traboulsi, E. I. Autosomal dominant retinitis pigmentosa secondary to pre-mRNA splicing-factor gene PRPF31 (RP11): review of disease mechanism and report of a family with a novel 3-base pair insertion. Ophthalmic Genet. 34, 183\u2013188 (2013).","journal-title":"Ophthalmic Genet."},{"key":"35361_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10633-018-9654-x","volume":"137","author":"S Bhatia","year":"2018","unstructured":"Bhatia, S., Goyal, S., Singh, I. R., Singh, D. & Vanita, V. A novel mutation in the PRPF31 in a North Indian adRP family with incomplete penetrance. Doc. Ophthalmol. 137, 103\u2013119 (2018).","journal-title":"Doc. Ophthalmol."},{"key":"35361_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-11-145","volume":"11","author":"I Audo","year":"2010","unstructured":"Audo, I. et al. Prevalence and novelty of PRPF31 mutations in French autosomal dominant rod-cone dystrophy patients and a review of published reports. BMC Med. Genet. 11, 145 (2010).","journal-title":"BMC Med. Genet."},{"key":"35361_CR13","first-page":"107","volume":"27","author":"FP Ruberto","year":"2021","unstructured":"Ruberto, F. P. et al. Heterozygous deletions of noncoding parts of the PRPF31 gene cause retinitis pigmentosa via reduced gene expression. Mol. Vis. 27, 107\u2013116 (2021).","journal-title":"Mol. Vis."},{"key":"35361_CR14","first-page":"1259","volume":"12","author":"D Mordes","year":"2006","unstructured":"Mordes, D. et al. Pre-mRNA splicing and retinitis pigmentosa. Mol. Vis. 12, 1259\u20131271 (2006).","journal-title":"Mol. Vis."},{"key":"35361_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/hmg\/11.1.87","volume":"11","author":"CF Chakarova","year":"2002","unstructured":"Chakarova, C. F. et al. Mutations in HPRP3, a third member of pre-mRNA splicing factor genes, implicated in autosomal dominant retinitis pigmentosa. Hum. Mol. Genet. 11, 87\u201392 (2002).","journal-title":"Hum. Mol. Genet."},{"key":"35361_CR16","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1093\/hmg\/ddu005","volume":"23","author":"X Chen","year":"2014","unstructured":"Chen, X. et al. PRPF4 mutations cause autosomal dominant retinitis pigmentosa. Hum. Mol. Genet. 23, 2926\u20132939 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"35361_CR17","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.ajhg.2011.04.008","volume":"88","author":"G Tanackovic","year":"2011","unstructured":"Tanackovic, G. et al. A missense mutation in PRPF6 causes impairment of pre-mRNA splicing and autosomal-dominant retinitis pigmentosa. Am. J. Hum. Genet. 88, 643\u2013649 (2011).","journal-title":"Am. J. Hum. Genet."},{"key":"35361_CR18","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1093\/hmg\/10.15.1555","volume":"10","author":"AB McKie","year":"2001","unstructured":"McKie, A. B. et al. Mutations in the pre-mRNA splicing factor gene PRPC8 in autosomal dominant retinitis pigmentosa (RP13). Hum. Mol. Genet. 10, 1555\u20131562 (2001).","journal-title":"Hum. Mol. Genet."},{"key":"35361_CR19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1097-2765(01)00305-7","volume":"8","author":"EN Vithana","year":"2001","unstructured":"Vithana, E. N. et al. A human homolog of yeast pre-mRNA splicing gene, PRP31, underlies autosomal dominant retinitis pigmentosa on chromosome 19q13.4 (RP11). Mol. Cell 8, 375\u2013381 (2001).","journal-title":"Mol. Cell"},{"key":"35361_CR20","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ajhg.2009.09.020","volume":"85","author":"C Zhao","year":"2009","unstructured":"Zhao, C. et al. Autosomal-dominant retinitis pigmentosa caused by a mutation in SNRNP200, a gene required for unwinding of U4\/U6 snRNAs. Am. J. Hum. Genet. 85, 617\u2013627 (2009).","journal-title":"Am. J. Hum. Genet."},{"key":"35361_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/sj.ejhg.5200797","volume":"10","author":"TJ Keen","year":"2002","unstructured":"Keen, T. J. et al. Mutations in a protein target of the Pim-1 kinase associated with the RP9 form of autosomal dominant retinitis pigmentosa. Eur. J. Hum. Genet. 10, 245\u2013249 (2002).","journal-title":"Eur. J. Hum. Genet."},{"key":"35361_CR22","doi-asserted-by":"publisher","first-page":"107950","DOI":"10.1016\/j.exer.2020.107950","volume":"192","author":"G Wheway","year":"2020","unstructured":"Wheway, G., Douglas, A., Baralle, D. & Guillot, E. Mutation spectrum of PRPF31, genotype-phenotype correlation in retinitis pigmentosa, and opportunities for therapy. Exp. Eye Res. 192, 107950 (2020).","journal-title":"Exp. Eye Res."},{"key":"35361_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1126\/science.1137924","volume":"316","author":"S Liu","year":"2007","unstructured":"Liu, S. et al. Binding of the human Prp31 Nop domain to a composite RNA-protein platform in U4 snRNP. Science 316, 115\u2013120 (2007).","journal-title":"Science"},{"key":"35361_CR24","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1093\/emboj\/21.5.1148","volume":"21","author":"OV Makarova","year":"2002","unstructured":"Makarova, O. V., Makarov, E. M., Liu, S., Vornlocher, H. P. & L\u00fchrmann, R. Protein 61K, encoded by a gene (PRPF31) linked to autosomal dominant retinitis pigmentosa, is required for U4\/U6*U5 tri-snRNP formation and pre-mRNA splicing. Embo j. 21, 1148\u20131157 (2002).","journal-title":"Embo j."},{"key":"35361_CR25","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1167\/iovs.10-5194","volume":"52","author":"JJ Graziotto","year":"2011","unstructured":"Graziotto, J. J. et al. Three gene-targeted mouse models of RNA splicing factor RP show late-onset RPE and retinal degeneration. Invest Ophthalmol. Vis. Sci. 52, 190\u2013198 (2011).","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"35361_CR26","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1093\/nar\/gkab003","volume":"49","author":"J Li","year":"2021","unstructured":"Li, J. et al. Prpf31 is essential for the survival and differentiation of retinal progenitor cells by modulating alternative splicing. Nucleic Acids Res. 49, 2027\u20132043 (2021).","journal-title":"Nucleic Acids Res."},{"key":"35361_CR27","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.1093\/hmg\/dds242","volume":"21","author":"AM Rose","year":"2012","unstructured":"Rose, A. M. et al. Expression of PRPF31 and TFPT: regulation in health and retinal disease. Hum. Mol. Genet. 21, 4126\u20134137 (2012).","journal-title":"Hum. Mol. Genet."},{"key":"35361_CR28","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1093\/hmg\/ddn212","volume":"17","author":"T Rio Frio","year":"2008","unstructured":"Rio Frio, T., Civic, N., Ransijn, A., Beckmann, J. S. & Rivolta, C. Two trans-acting eQTLs modulate the penetrance of PRPF31 mutations. Hum. Mol. Genet. 17, 3154\u20133165 (2008).","journal-title":"Hum. Mol. Genet"},{"key":"35361_CR29","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1089\/gtmb.2018.0036","volume":"22","author":"D Xie","year":"2018","unstructured":"Xie, D. et al. Targeted next generation sequencing revealed novel prpf31 mutations in autosomal dominant retinitis pigmentosa. Genet Test. Mol. Biomark. 22, 425\u2013432 (2018).","journal-title":"Genet Test. Mol. Biomark."},{"key":"35361_CR30","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","volume":"358","author":"AM Maguire","year":"2008","unstructured":"Maguire, A. M. et al. Safety and efficacy of gene transfer for Leber\u2019s congenital amaurosis. N. Engl. J. Med. 358, 2240\u20132248 (2008).","journal-title":"N. Engl. J. Med."},{"key":"35361_CR31","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.omtm.2019.10.014","volume":"15","author":"EM Brydon","year":"2019","unstructured":"Brydon, E. M. et al. AAV-mediated gene augmentation therapy restores critical functions in mutant prpf31(+\/\u2212) ipsc-derived rpe cells. Mol. Ther. Methods Clin. Dev. 15, 392\u2013402 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"35361_CR32","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.1167\/iovs.08-3275","volume":"50","author":"K Bujakowska","year":"2009","unstructured":"Bujakowska, K. et al. Study of gene-targeted mouse models of splicing factor gene Prpf31 implicated in human autosomal dominant retinitis pigmentosa (RP). Invest Ophthalmol. Vis. Sci. 50, 5927\u20135933 (2009).","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"35361_CR33","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/j.ajpath.2014.06.026","volume":"184","author":"MH Farkas","year":"2014","unstructured":"Farkas, M. H. et al. Mutations in pre-mRNA processing factors 3, 8, and 31 cause dysfunction of the retinal pigment epithelium. Am. J. Pathol. 184, 2641\u20132652 (2014).","journal-title":"Am. J. Pathol."},{"key":"35361_CR34","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/hmg\/ddq473","volume":"20","author":"B Linder","year":"2011","unstructured":"Linder, B. et al. Systemic splicing factor deficiency causes tissue-specific defects: a zebrafish model for retinitis pigmentosa. Hum. Mol. Genet. 20, 368\u2013377 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"35361_CR35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1750-1326-6-56","volume":"6","author":"J Yin","year":"2011","unstructured":"Yin, J., Brocher, J., Fischer, U. & Winkler, C. Mutant Prpf31 causes pre-mRNA splicing defects and rod photoreceptor cell degeneration in a zebrafish model for Retinitis pigmentosa. Mol. Neurodegener. 6, 56 (2011).","journal-title":"Mol. Neurodegener."},{"key":"35361_CR36","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s13238-010-0035-9","volume":"1","author":"P Ray","year":"2010","unstructured":"Ray, P. et al. The splicing factor Prp31 is essential for photoreceptor development in Drosophila. Protein Cell 1, 267\u2013274 (2010).","journal-title":"Protein Cell"},{"key":"35361_CR37","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1126\/science.aat5011","volume":"361","author":"GJ Knott","year":"2018","unstructured":"Knott, G. J. & Doudna, J. A. CRISPR-Cas guides the future of genetic engineering. Science 361, 866\u2013869 (2018).","journal-title":"Science"},{"key":"35361_CR38","doi-asserted-by":"publisher","first-page":"189ra176","DOI":"10.1126\/scitranslmed.3005708","volume":"5","author":"D Dalkara","year":"2013","unstructured":"Dalkara, D. et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci. Transl. Med. 5, 189ra176 (2013).","journal-title":"Sci. Transl. Med."},{"key":"35361_CR39","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/gt.2011.163","volume":"19","author":"D Dalkara","year":"2012","unstructured":"Dalkara, D. et al. Enhanced gene delivery to the neonatal retina through systemic administration of tyrosine-mutated AAV9. Gene Ther. 19, 176\u2013181 (2012).","journal-title":"Gene Ther."},{"key":"35361_CR40","doi-asserted-by":"crossref","unstructured":"Xi, Z., \u00d6zt\u00fcrk, B. E., Johnson, M. E., Stauffer, W. R. & Byrne, L. C. Quantitative single-cell transcriptome-based ranking of engineered AAVs in human retinal explants. bioRxiv (2021).","DOI":"10.1101\/2021.09.27.461256"},{"key":"35361_CR41","doi-asserted-by":"publisher","unstructured":"Ozturk, B. E. et al. scAAVengr, a transcriptome-based pipeline for quantitative ranking of engineered AAVs with single-cell resolution. Elife 10, https:\/\/doi.org\/10.7554\/eLife.64175 (2021).","DOI":"10.7554\/eLife.64175"},{"key":"35361_CR42","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1350-9462(97)00012-8","volume":"17","author":"AH Milam","year":"1998","unstructured":"Milam, A. H., Li, Z. Y. & Fariss, R. N. Histopathology of the human retina in retinitis pigmentosa. Prog. Retin Eye Res. 17, 175\u2013205 (1998).","journal-title":"Prog. Retin Eye Res."},{"key":"35361_CR43","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1167\/iovs.07-1513","volume":"49","author":"D Trifunovic","year":"2008","unstructured":"Trifunovic, D. et al. A high-resolution RNA expression atlas of retinitis pigmentosa genes in human and mouse retinas. Invest Ophthalmol. Vis. Sci. 49, 2330\u20132336 (2008).","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"35361_CR44","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1523\/JNEUROSCI.2399-04.2005","volume":"25","author":"L Yuan","year":"2005","unstructured":"Yuan, L., Kawada, M., Havlioglu, N., Tang, H. & Wu, J. Y. Mutations in PRPF31 inhibit pre-mRNA splicing of rhodopsin gene and cause apoptosis of retinal cells. J. Neurosci. 25, 748\u2013757 (2005).","journal-title":"J. Neurosci."},{"key":"35361_CR45","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/ncb3201","volume":"17","author":"G Wheway","year":"2015","unstructured":"Wheway, G. et al. An siRNA-based functional genomics screen for the identification of regulators of ciliogenesis and ciliopathy genes. Nat. Cell Biol. 17, 1074\u20131087 (2015).","journal-title":"Nat. Cell Biol."},{"key":"35361_CR46","doi-asserted-by":"publisher","unstructured":"Sahel, J. A. et al. Partial recovery of visual function in a blind patient after optogenetic therapy. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-021-01351-4 (2021).","DOI":"10.1038\/s41591-021-01351-4"},{"key":"35361_CR47","doi-asserted-by":"publisher","first-page":"e15860","DOI":"10.1371\/journal.pone.0015860","volume":"6","author":"H Cao","year":"2011","unstructured":"Cao, H. et al. Temporal and tissue specific regulation of RP-associated splicing factor genes PRPF3, PRPF31 and PRPC8\u2013implications in the pathogenesis of RP. PLoS One 6, e15860 (2011).","journal-title":"PLoS One"},{"key":"35361_CR48","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1167\/iovs.03-0253","volume":"44","author":"EN Vithana","year":"2003","unstructured":"Vithana, E. N. et al. Expression of PRPF31 mRNA in patients with autosomal dominant retinitis pigmentosa: a molecular clue for incomplete penetrance? Invest Ophthalmol. Vis. Sci. 44, 4204\u20134209 (2003).","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"35361_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10020-019-0124-z","volume":"26","author":"L Vald\u00e9s-S\u00e1nchez","year":"2019","unstructured":"Vald\u00e9s-S\u00e1nchez, L. et al. Retinal pigment epithelium degeneration caused by aggregation of PRPF31 and the role of HSP70 family of proteins. Mol. Med. 26, 1 (2019).","journal-title":"Mol. Med."},{"key":"35361_CR50","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/mt.2009.181","volume":"17","author":"D Dalkara","year":"2009","unstructured":"Dalkara, D. et al. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol. Ther. 17, 2096\u20132102 (2009).","journal-title":"Mol. Ther."},{"key":"35361_CR51","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/BF02172971","volume":"226","author":"S Heegaard","year":"1988","unstructured":"Heegaard, S., Jensen, O. A. & Prause, J. U. Structure of the vitread face of the monkey optic disc (Macaca mulatta). SEM on frozen resin-cracked optic nerveheads supplemented by TEM and immunohistochemistry. Graefes Arch. Clin. Exp. Ophthalmol. 226, 377\u2013383 (1988).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"35361_CR52","doi-asserted-by":"publisher","first-page":"W171","DOI":"10.1093\/nar\/gkz365","volume":"47","author":"K Labun","year":"2019","unstructured":"Labun, K. et al. CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing. Nucleic Acids Res. 47, W171\u2013W174 (2019).","journal-title":"Nucleic Acids Res."},{"key":"35361_CR53","doi-asserted-by":"publisher","first-page":"W242","DOI":"10.1093\/nar\/gky354","volume":"46","author":"JP Concordet","year":"2018","unstructured":"Concordet, J. P. & Haeussler, M. CRISPOR: intuitive guide selection for CRISPR\/Cas9 genome editing experiments and screens. Nucleic Acids Res. 46, W242\u2013W245 (2018).","journal-title":"Nucleic Acids Res."},{"key":"35361_CR54","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/nprot.2006.207","volume":"1","author":"JC Grieger","year":"2006","unstructured":"Grieger, J. C., Choi, V. W. & Samulski, R. J. Production and characterization of adeno-associated viral vectors. Nat. Protoc. 1, 1412\u20131428 (2006).","journal-title":"Nat. Protoc."},{"key":"35361_CR55","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1089\/hgtb.2011.034","volume":"23","author":"C Aurnhammer","year":"2012","unstructured":"Aurnhammer, C. et al. Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. Hum. Gene Ther. Methods 23, 18\u201328 (2012).","journal-title":"Hum. Gene Ther. Methods"},{"key":"35361_CR56","doi-asserted-by":"crossref","unstructured":"Gombash Lampe, S. E., Kaspar, B. K. & Foust, K. D. Intravenous injections in neonatal mice. J. Vis. Exp. e52037 (2014).","DOI":"10.3791\/52037"},{"key":"35361_CR57","doi-asserted-by":"publisher","unstructured":"Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. 17, 3 https:\/\/doi.org\/10.14806\/ej.17.1.200 (2011).","DOI":"10.14806\/ej.17.1.200"},{"key":"35361_CR58","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/nbt.3583","volume":"34","author":"L Pinello","year":"2016","unstructured":"Pinello, L. et al. Analyzing CRISPR genome-editing experiments with CRISPResso. Nat. Biotechnol. 34, 695\u2013697 (2016).","journal-title":"Nat. Biotechnol."},{"key":"35361_CR59","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417\u2013419 (2017).","journal-title":"Nat. Methods"},{"key":"35361_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35361-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35361-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35361-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T17:08:17Z","timestamp":1671210497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35361-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["35361"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-35361-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,13]]},"assertion":[{"value":"5 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.A.S. is a co-founder of Avista Therapeutics and Vegavect. L.C.B. is an inventor on patent applications on AAV capsid variants and a co-founder of Avista Therapeutics and Vegavect. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7695"}}